Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$750,000.00
Nov 1, 2014
The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in men who have sex with men
$26,302.00
Oct 30, 2014
$300,000.00
Oct 1, 2014
Evaluation of viral sensitizer technology in improving egg-based influenza vaccine manufacturing processes
$159,000.00
Oct 1, 2014
Evaluation of a Novel Chlamydia Vaccine Based on Type III Secretion Proteins
$1,113,771.00
Oct 1, 2014
Long-term immunogenicity and clinical efficacy of the quadrivalent HPV vaccine in HIV positive girls and women
$159,612.00
Oct 1, 2014
Development of a peptide mimetic vaccine for prevention of Epstein-Barr virus infectious mononucleosis and related cancers.
$305,910.00
Oct 1, 2014
A phase 1 Randomized, Single-Centre, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSV¿-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Subjects
$150,000.00
Sep 1, 2014
Immunological Characterization of Varicella Zoster Virus (VZV) as a Replicating Viral Vector for an HIV Vaccine
$150,000.00
Aug 1, 2014
Application of Protein Capsular Matrix Vaccine Technology to the Development of a Novel Form of Killed Whole Cell Vaccines
$110,000.00
Jul 1, 2014
Linking laboratory and administrative data to study influenza and influenza vaccine epidemiology